What is the official website of AbbVie ?

The official website of AbbVie is http://www.abbvie.com.

What is AbbVie's cybersecurity risk score?

AbbVie has an AI-generated cybersecurity risk score of 827 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has AbbVie experienced?

According to Rankiteo, AbbVie currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has AbbVie been affected by any supply chain cyber incidents ?

According to Rankiteo, AbbVie has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does AbbVie have SOC 2 Type 1 certification ?

According to Rankiteo, AbbVie is not certified under SOC 2 Type 1.

Does AbbVie have SOC 2 Type 2 certification ?

According to Rankiteo, AbbVie does not hold a SOC 2 Type 2 certification.

Does AbbVie comply with GDPR ?

According to Rankiteo, AbbVie is not listed as GDPR compliant.

Does AbbVie have PCI DSS certification ?

According to Rankiteo, AbbVie does not currently maintain PCI DSS compliance.

Does AbbVie comply with HIPAA ?

According to Rankiteo, AbbVie is not compliant with HIPAA regulations.

Does AbbVie have ISO 27001 certification ?

According to Rankiteo,AbbVie is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does AbbVie operate in ?

AbbVie operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does AbbVie have ?

AbbVie employs approximately 61,106 people worldwide.

Does AbbVie own any subsidiaries ?

AbbVie presently has no subsidiaries across any sectors.

How many LinkedIn followers does AbbVie have ?

AbbVie's official LinkedIn profile has approximately 2,051,823 followers.

What is the NAICS classification code for AbbVie ?

AbbVie is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does AbbVie have a Crunchbase profile ?

Yes, AbbVie has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/abbvie.

Does AbbVie have a LinkedIn profile ?

Yes, AbbVie maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/abbvie.

How many cybersecurity incidents has AbbVie experienced ?

As of September 17, 2026, Rankiteo reports that AbbVie has experienced 2 cybersecurity incidents.

How many peer or competitor companies does AbbVie have ?

AbbVie has an estimated 5,766 peer or competitor companies worldwide.

What types of cybersecurity incidents has AbbVie faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Vulnerability.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

AbbVie

Boost Score +25 with badge (5 left)

827

/1000

Good

852

/1000

Very Good

AbbVie Vendor Cyber Rating & Cyber Score

abbvie.com

cb in

Add Your Compliance Badge

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

AbbVie

AbbVie CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AbbVie

Vulnerability

100

4/2026

EGAABB177565877...

AbbVie

Breach

100

6/2023

ABB0473723

Loading…

A.I.

AbbVie Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for AbbVie

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

AbbVie has 30.56% fewer incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs All-Companies Average (This Year)

AbbVie has 2.91% fewer incidents than the average of all companies with at least one recorded incident.

Incident Types AbbVie vs Pharmaceutical Manufacturing Industry Avg (This Year)

AbbVie reported 1 incidents this year: 0 cyber attacks, 0 ransomware, 1 vulnerabilities, 0 data breaches, compared to industry peers with at least 1 incident.

Incident History - AbbVie (X = Date, Y = Severity)

Loading…

SUBSIDIARY

AbbVie Subsidiaries

AbbVie

Pharmaceutical Manufacturing

Website: http://www.abbvie.com

Company Size: 10,001+ employees

Allergan Aesthetics, an AbbVie CompanyPharmaceutical Manufacturing

Allergan Medical InstitutePharmaceutical Manufacturing

BOTOX® Cosmetic (onabotulinumtoxinA)Pharmaceutical Manufacturing

Allergan Aesthetics Plastic and Regenerative Medicine PortfolioMedical Equipment Manufacturing

Natrelle Breast ImplantsPharmaceutical Manufacturing

AbbVie | OncologyPharmaceutical Manufacturing

AbbVie | DeutschlandPharmaceutical Manufacturing

AbbVie | UKPharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

AbbVie Contract ManufacturingPharmaceutical Manufacturing

AbbVie | VirologyPharmaceutical Manufacturing

Loading…

AbbVie Similar Companies

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Loading…

NEWS

AbbVie CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

August 29, 2026 12:12 PM

AbbVie (ABBV) Q2 2026 Earnings Call Transcript

AbbVie is among the largest pharmaceutical companies by revenue, and provides therapeutic solutions in areas including immunology, oncology,...

Read Article

August 29, 2026 11:55 AM

AbbVie (ABBV) Q1 2026 Earnings Call Transcript

AbbVie is among the largest pharmaceutical companies by revenue, and provides therapeutic solutions in areas including immunology, oncology,...

Read Article

June 30, 2026 07:00 AM

US House Committee Opens Investigation Into Merck, AbbVie China Drug Trials

US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health...

Read Article

February 20, 2026 08:00 AM

AbbVie Inc. SEC 10-K Report

AbbVie Inc., a global biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of...

Read Article

April 25, 2025 07:00 AM

AbbVie (ABBV) Q1 2025 Earnings Call Transcript

AbbVie is among the largest pharmaceutical companies by revenue, and provides therapeutic solutions in areas including immunology, oncology,...

Read Article

January 10, 2025 08:00 AM

AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel...

Read Article

December 24, 2024 08:00 AM

Action likely against AbbVie executive who signed self-declaration

American drug major AbbVie Healthcare's Indian arm, which is under the scanner for sponsoring foreign trips of 30 doctors in violation of...

Read Article

August 12, 2024 07:00 AM

QARA Professionals Question a Future with Cybersecurity Issues, US Litigation, and the EU AI Act

At a private event held amid the fallout from the CrowdStrike incident, cybersecurity issues took a front seat, with the consequences of the...

Read Article

March 07, 2023 08:00 AM

AbbVie's Newly Retired Laura Schumacher Remained Among Highest-Paid Legal Chiefs in Final Year

Better than a gold watch, 2022 compensation for recently retired AbbVie Chief Legal Officer Laura Schumacher topped $11.6 million,...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-65388

SUMMARY

A remote attacker who controls a container registry may be able to direct a client's token request to a host of the attacker's choice, and disclose the victim's registry credentials to that host. This vulnerability is addressed in containerization version 0.41.0.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://github.com/apple/containerization/security/advisories/GHSA-mx96-5vvg-x2mg

CVE-2026-61599

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, the djust live transport resolves the LiveView to mount from a client-supplied dotted path by calling `__import__(module_path, ...)`. The module is imported — running its top-level code (import side effects) — before the framework checks that the resolved object is a `LiveView` subclass and before any per-view authentication. The `LIVEVIEW_ALLOWED_MODULES` allowlist that should contain this is fail-open (`if allowed_modules:` — skipped when the setting is unset, the framework default) and uses loose `startswith` matching. An unauthenticated WebSocket client (the WS handshake does not require auth; per-view auth runs only after import + instantiate) can therefore send a `mount` / `live_redirect_mount` / `url_change` frame (or an SSE mount) with `view = "<any.importable.module>.AnyName"` and cause the server to import — and execute the top-level code of — any importable Python module by name. Version 1.0.7 fixes the issue with a fail-closed resolution gate (`djust._view_resolution.is_view_import_allowed`): a client view path resolves only if (a) its module is already loaded (`sys.modules` — so resolving runs no new code; URL-routed views loaded by URLconf at startup keep working with zero config) or (b) it matches `LIVEVIEW_ALLOWED_MODULES` on a module-segment boundary (explicit opt-in for lazily-imported views). The gate runs before `__import__` at all three sinks (+ defense-in-depth inside `_instantiate_view`). As a workaround, set `LIVEVIEW_ALLOWED_MODULES` to the narrow list of modules that contain your mountable LiveView classes. (Note: pre-patch the allowlist is `startswith`-matched and the import still precedes the subclass check, so this is mitigation, not a complete fix.)

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: )

cvss4

Base Score: 8.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-61596

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, djust's per-object authorization (`get_object` + `has_object_permission`, ADR-017) was enforced on the WebSocket mount and event paths but not on three other render entry points: (a) the initial HTTP GET render, (b) SPA `url_change` navigation, and (c) `{% live_render %}` embedded child views. An authenticated user could therefore view (and on some paths act on) an object they are not authorized for by loading the page directly, navigating to it via SPA url-change, or composing it as an embedded child — a classic IDOR / broken object-level access control on object-scoped views. This is fixed in djust 1.0.7. All render entry points now route through a shared `enforce_object_permission` chokepoint: HTTP GET returns 403, `url_change` emits a `permission_denied` frame and skips the render, and `{% live_render %}` (eager + lazy) refuses the embed. Views without a custom `get_object` are unaffected (no-op). No reliable workaround short of upgrading. Do not expose object-scoped views through the HTTP-GET / url_change / live_render paths until patched.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:L/A:N

Impact Score

4.2

Exploitability

2.8

REFERENCES

CVE-2026-61589

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, the WebSocket `handle_mount` and `ViewRuntime._build_request` rebuild an `HttpRequest` via `RequestFactory().get(...)` with no `HTTP_HOST`, so `request.get_host()` defaulted to `"testserver"` on the live path. Host/subdomain/domain `TenantResolver`s then misresolved the tenant — `None` on the live path while the HTTP path resolved correctly. With `STRICT_MODE=False` the tenant-scoped managers returned unscoped rows (cross-tenant disclosure); with the default they returned an empty queryset (broken tenancy). This is fixed in djust 1.0.7. The handshake Host is extracted from the ASGI scope, validated against `ALLOWED_HOSTS` (the same logic as the CSWSH Origin gate, parsed with Django's `split_domain_port` so malformed Hosts are rejected at the boundary), and propagated — with the TLS scheme — into the reconstructed request, so live-path tenant resolution matches HTTP exactly. There is no known workaround on the live path short of upgrading. Users are most exposed when combined with `STRICT_MODE=False`.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: 6.3)

cvss3

Base Score: 6.3

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:N/A:N

Impact Score

Exploitability

1.8

REFERENCES

CVE-2026-61588

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, when a Django `Model` instance is assigned to a public view attribute, djust serialized it to the client with no sensitive-field denylist — sending fields such as `password` (the hash), privilege flags (e.g. `is_staff` / `is_superuser`), tokens, and other PII to the browser. Because exposing model objects to templates is a normal djust pattern, this could leak credentials/PII without the developer realizing the full object crossed the wire. This is fixed in djust 1.0.7. Model serialization applies a secure-by-default sensitive-field denylist (password/hash/token/secret-style fields and known privilege flags are withheld) with an identity-subset fallback. As a workaround, keep `Model` instances on `_private` attributes and expose only the specific fields needed, until patched.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

AbbVie Vendor Cyber Rating & Cyber Score

AbbVie A.I CyberSecurity Scoring

AbbVie CyberSecurity News & History

AbbVie Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for AbbVie

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types AbbVie vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - AbbVie (X = Date, Y = Severity)

AbbVie Subsidiaries

AbbVie

AbbVie Similar Companies

Astellas Pharma

Sandoz

Viatris

MANKIND PHARMA LTD

UCB

Merck

Takeda

Glenmark Pharmaceuticals

Hikma Pharmaceuticals

AbbVie CyberSecurity News

AbbVie (ABBV) Q2 2026 Earnings Call Transcript

AbbVie (ABBV) Q1 2026 Earnings Call Transcript

US House Committee Opens Investigation Into Merck, AbbVie China Drug Trials

AbbVie Inc. SEC 10-K Report

AbbVie (ABBV) Q1 2025 Earnings Call Transcript

AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug

Action likely against AbbVie executive who signed self-declaration

QARA Professionals Question a Future with Cybersecurity Issues, US Litigation, and the EU AI Act

AbbVie's Newly Retired Laura Schumacher Remained Among Highest-Paid Legal Chiefs in Final Year

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

AbbVie CyberSecurity News & History

AbbVie Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for AbbVie

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types AbbVie vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - AbbVie (X = Date, Y = Severity)

AbbVie Subsidiaries

AbbVie

AbbVie Similar Companies

Astellas Pharma

Sandoz

Viatris

MANKIND PHARMA LTD

UCB

Merck

Takeda

Glenmark Pharmaceuticals

Hikma Pharmaceuticals

AbbVie CyberSecurity News

AbbVie (ABBV) Q2 2026 Earnings Call Transcript

AbbVie (ABBV) Q1 2026 Earnings Call Transcript

US House Committee Opens Investigation Into Merck, AbbVie China Drug Trials

AbbVie Inc. SEC 10-K Report

AbbVie (ABBV) Q1 2025 Earnings Call Transcript

AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug

Action likely against AbbVie executive who signed self-declaration

QARA Professionals Question a Future with Cybersecurity Issues, US Litigation, and the EU AI Act

AbbVie's Newly Retired Laura Schumacher Remained Among Highest-Paid Legal Chiefs in Final Year

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo